Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
深圳市信立泰生物医疗工程有限公司拟股权置换所涉及深圳市科奕顿生物医疗科技有限公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Evaluation Report) and is prepared by Guangdong Union Trust Evaluation Co., Ltd. It is an asset appraisal report related to the equity swap involving Shenzhen Xintai Medical Engineering Co., Ltd. and Shenzhen Keyidun Biomedical Technology Co., Ltd. The report includes detailed valuation methods, asset and liability summaries, financial data, and legal disclaimers. It is a comprehensive asset valuation report rather than a financial statement or regulatory filing. It does not correspond to any of the typical corporate filings like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Management Reports (MDA). It is a standalone asset appraisal report, which fits best under Audit Report / Information (AR) category as it involves valuation and applied accounting principles but is not a full annual report. The document length is substantial and contains detailed substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the most appropriate classification is AR (Audit Report / Information). Q3 2021
2022-03-28 Chinese
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the '2021 Annual Supervisory Board Work Report' of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the supervisory board's activities throughout 2021, including meetings held, oversight of financial reports, internal controls, compliance with laws and regulations, and supervision of various company operations. It references the review and approval of quarterly reports, half-year reports, and the annual report for 2021, but the document itself is a supervisory board report summarizing oversight activities rather than the full annual report or financial statements. The length is 4338 characters, which is relatively short and consistent with a report or summary rather than a full annual report. The content focuses on supervisory board work and oversight rather than presenting full financial data or management discussion. Therefore, the document fits best under the category of Management Reports (MDA), which includes management's detailed explanation of financial results, business trends, and outlook, or in this case, the supervisory board's report on oversight activities. It is not an announcement or certification, so RNS or RPA are not appropriate. It is not a full Annual Report (10-K) or Interim Report (IR) because it does not contain full financial statements or substantive financial data. Hence, the classification is MDA with high confidence.
2022-03-28 Chinese
2021年度独立董事述职报告（何素英）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, on-site inspections, and other supervisory activities during the 2021 fiscal year. The content is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or audit results, nor is it a regulatory filing or announcement of voting results. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and reports of a board member (independent director). The document length is 2449 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2022-03-28 Chinese
2021年度独立董事述职报告（ZHANG MENG）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision activities, and resignation. The content focuses on the independent director's duties, opinions, and oversight rather than financial results or audit opinions. It is a report by a board member about their activities and governance role, not an annual report, audit report, or financial statement. This fits the category of Board/Management Information (MANG), which includes announcements related to board members and senior management activities, including reports by directors about their work and changes in board composition (such as the resignation and replacement of the independent director). The document length is under 5,000 characters, but it is a substantive report by a board member, not a mere announcement of a report publication. Therefore, the best classification is MANG with high confidence.
2022-03-28 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司2021年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities company regarding the storage and use of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the fiscal year 2021. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial figures about the amount raised, usage, storage, and management of the funds. The document is a formal audit or verification report on the use of capital raised by the company, not the company's annual report or earnings release. It is not a simple announcement but a substantive report on the capital usage compliance and management. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on the application of raised funds, including compliance with regulatory requirements and internal controls. The document length (6279 characters) and content support this classification with high confidence. FY 2021
2022-03-28 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm regarding the company's non-operating funds occupied by controlling shareholders and other related parties. It includes an audit opinion, responsibilities of management and auditors, and a detailed summary table of the non-operating funds occupied and other related party transactions for the fiscal year 2021. The document is titled as an "audit report" and contains detailed financial data and audit conclusions. It is not a full annual report but a standalone audit report focused on a specific aspect of the company's financials. The document length is under 5,000 characters but contains substantive financial data and audit opinion, so it is not merely an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2021
2022-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.